clobetasol propionate topical / Generic mfg. - LARVOL DELTA

Using Disease Symptomatology to Guide Treatment in Patients with Central Centrifugal Cicatricial Alopecia: Introduction of C-CAT Scoring Tool. (PubMed, Skin Appendage Disord) - "Intralesional kenalog injections and topical clobetasol were the most commonly used therapies...The C-CAT provides a structured, quantitative method to assess CCCA severity, which facilitates tracking of disease improvement for the majority of patients with targeted therapy. While the subjective nature of some C-CAT components may lead to inter-rater variability, this tool promotes personalized, symptom-based treatment and supports clinicians and patients in understanding this complex condition."

Journal • Alopecia • Dermatology • Immunology • Pain • Pruritus

EMPATIA: Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: University of Palermo

New P2 trial • Dermatology • Dermatopathology • Lichen Planus • Pain

A case of Hailey-Hailey disease accompanied by Cushing's syndrome and adrenal insufficiency due to long-term usage of topical steroids with review of literature. (PubMed, Endocr J) - "Following the initiation of hydrocortisone replacement therapy, psychiatric symptoms, impaired glucose tolerance, and osteoporotic fractures emerged, suggesting exacerbation of iatrogenic Cushing's syndrome. Gradual dose reduction, close endocrine monitoring, and individualized tapering strategies are essential to prevent severe outcomes. Clinicians should be aware of potential adrenal suppression and consider endocrine evaluation in patients receiving prolonged, high-dose topical corticosteroid therapy."

Journal • Cushing’s Disease • Endocrine Disorders • Genetic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Psychiatry • Renal Disease

Continuous manufacturing of a topical hydrogel with clobetasol propionate-loaded liposomes using QbD methodology. (PubMed, Int J Pharm) - "Thus, this study demonstrates the successful development of topical CP-liposomal hydrogels and the feasibility to continuously process nano-drug carriers into a semi-solid formulation using a flexible continuous mixing line. Importantly, these findings support a translational manufacturing pathway toward the fully continuous end-to-end manufacturing of nano-based semi-solids."

Journal

Topical Steroid Induced Cushing Syndrome with Adrenal Insufficiency in a Pediatric Patient (ENDO 2025) - "He was started and maintained temporarily on metformin treatment...Clobetasol propionate treatment was discontinued...To address the adrenal insufficiency, hydrocortisone was given in physiologic dose and was discontinued after three months, after a recovery of the basal morning serum cortisol was documented...Selecting less potent steroids, limiting the duration of exposure and using steroid sparing medications should be considered. In addition, parental education regarding close monitoring of treatment and potential side effects cannot be overemphasized."

Clinical • Acne Vulgaris • Atopic Dermatitis • Cushing’s Disease • Dermatitis • Dermatology • Endocrine Disorders • Genetic Disorders • Immunology • Nephrology • Obesity • Pediatrics • Renal Disease

Localized Morphea in a Pediatric Patient Successfully Treated With Topical Ruxolitinib. (PubMed, Pediatr Dermatol) - "Literature on the treatment of localized recalcitrant disease is sparse. We report a case of biopsy-confirmed morphea in a 17-year-old female that significantly improved with topical ruxolitinib 1.5% cream and intralesional triamcinolone after treatment with clobetasol ointment failed."

Journal • Dermatology • Fibrosis • Immunology • Pediatrics • Rare Diseases • Scleroderma • Systemic Sclerosis

Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis. (PubMed, Br J Clin Pharmacol) - "Systemic and local exposure to CP increases with impaired skin barrier in AD and larger application area. Given the recommended maximum dose of 50 g per week, CP should not be applied to an area of more than 30% of the BSA. Availability of this model will allow extrapolation of CP pharmacokinetics from adults to children."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

The efficacy and safety of pharmacological treatment of desquamative gingivitis: a systematic review. (PubMed, BMC Oral Health) - "Clobetasol and tacrolimus remain first-line therapies for DG, supported by their efficacy and manageable safety profiles. Platelet-rich plasma and nano-vitamin-based therapies offer potential alternatives but require further validation. Given the variability in treatment protocols, standardized guidelines and long-term studies are needed to optimize the clinical management."

Journal • Review • Candidiasis • Dental Disorders • Hematological Disorders • Pain

Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial. (PubMed, Int Immunopharmacol) - "This study suggests that tofacitinib may effectively halt disease progression in LPP, emphasizing its potential as a treatment option."

Clinical • Journal • Alopecia • Dermatology • Inflammation • Lichen Planus

Local and systemic effects of topical betulinic acid in a psoriasis-like inflammation model in mice. (PubMed, Planta Med) - "Imiquimod was applied to induce psoriasis-like skin inflammation in mice (except in the untreated group) every 24 hours for 5 days. BA uniquely normalized IFNγ levels without causing intolerable toxicity. Using an animal model of psoriatic skin inflammation, our findings support BA as a strong candidate for clinical translation, warranting further studies on its safety, pharmacokinetics, and optimal dosage in humans, potentially leading to randomized controlled trials in psoriasis patients."

Journal • Preclinical • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • IFNG • IL17A • TGFB1 • TNFA

Dramatic clearance of extensive psoriasis in a pediatric patient with upadacitinib (CDA 2025) - "Introduction : Psoriasis is a chronic inflammatory skin condition that commonly presents on the knees, elbows, trunk, and scalp, but can involve the palmoplantar surfaces. The patient presented with severe palmoplantar psoriasis at age 3, progressing to widespread disease by age 8, with genital involvement, painful fissures, and impaired mobility. He underwent extensive treatments, including methotrexate, acitretin, cyclosporine, ustekinumab, ixekizumab, apremilast, secukinumab, and deucravacitinib, alongside topical therapies including clobetasol, roflumilast, halobetasol and betamethasone diproprionate-based preparations. Despite moderate responses to some regimens, sustained control was not achieved, and treatment side effects, including elevated liver enzymes, dyslipidemia and gastrointestinal discomfort, further limited options."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dyslipidemia • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Metabolic Disorders • Pain • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Over the counter use of topical corticosteroid for skin conditions among patients before attending skin specialist clinic in Nepal: A qualitative study. (PubMed, PLOS Glob Public Health) - "Among the 31 individuals diagnosed with Dermatophytosis, Melasma, Eczema, common treatments included use of Sonaderm (Clobetasol, Gentamycin and Miconazole), Derma-KT (Clobetasol, Gentamicin, Ketoconazole and Iodochlorhydroxyquinoline) and steroid-infused products from non-medical sources for prolonged periods of time, exposing patients to transient recovery and perpetuating a vicious cycle of OTC treatment seeking until patients failed to recover. OTC use of topical medications poses significant challenges, often leading to complicated skin cases that present late at skin-specialist clinics. A multi-pronged public and community engagement approach is critical to curb the treatment seeking dynamics among patients developing skin conditions."

Journal • Atopic Dermatitis • Dermatology • Dermatopathology • Immunology • Infectious Disease

The most powerful topical anti-inflammatory: the cautionary and enlightening story of SKIN-CAP. (PubMed, Dermatol Online J) - "Better adherence to the SKIN-CAP product may explain the efficacy. The SKIN-CAP story provides insights into the need for healthy skepticism, the importance of treatment adherence, and ways to encourage better adherence to topical medications."

Journal • Review • Dermatology • Immunology • Psoriasis

Diagnosing Drug-Induced Sweet Syndrome With Target-Like Lesions Amidst Malignancy And Infection (EAACI 2025) - "Topical clobetasol ointment was applied...In Allergy, drug chart remains essential in establishing drug relevance with the clinical manifestation. Research and reports across the world provide venue that impacts the day-to-day undertakings of Medicine as well as in Allergy diseases."

Allergy • Immunology

Detailed Clinical Characterization of a Large Cohort of Chronic Spontaneous Urticaria Patients (EAACI 2025) - "Other common treatments were fexofenadine (143 patients, 35.6% non-responders), diphenhydramine (134 patients, 32.1% non-responders), hydroxyzine (99 patients, 46.5% non-responders) and levocetirizine (76 patients, 23.7% non-responders). Topical steroids, including triamcinolone 0.1% (39 patients, 23.1% non-responders) and hydrocortisone 1% (14 patients, 42.9% non-responders), were utilized the least. A negligible portion of the study population (<20) patients trialed other topicals, such as clobetasol and tacrolimus, with outcomes largely unquantified. Omalizumab was administered to 146 patients, with 35 patients experiencing either no response or partial response to this therapy...Of 154 total patients who were prescribed prednisone for comorbid asthma attack, 124 were complete to partial responders, and 76% reported their symptoms returned after stopping the OCS. Conclusion The frequent prevalence of atopic comorbidities and refractory urticaria in CSU patients..."

Clinical • Allergic Rhinitis • Allergy • Atopic Dermatitis • Dermatitis • Immunology • Inflammation

Extravascular leakage of dexrazoxane that occurred in a patient with diffuse large B-cell lymphoma: a case report. (PubMed, J Pharm Health Care Sci) - "This case report is one of the first to document the management of dexrazoxane extravascular leakage using topical steroids, effectively preventing severe outcomes. The findings suggest that topical steroids may be a desirable treatment approach for dexrazoxane leakage. Prompt intervention and interdisciplinary care contributed to the favorable outcome. This case highlights the need for further research and guideline refinement to optimize the management of inflammatory extravascular leakage."

Journal • B Cell Lymphoma • Dermatology • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

VULVIE: Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus (clinicaltrials.gov) - P4 | N=212 | Completed | Sponsor: Medstar Health Research Institute | Active, not recruiting ➔ Completed

Trial completion • Dermatology

XPC gene variation in an individual with generalized eruptive keratoacanthomas of grzybowski (SID 2025) - "Treatments included topical 5-fluorouracil, 5-fluorouracil + calcipotriene cream, imiquimod, triamcinolone cream, and clobetasol ointment; injected 5-fluorouracil and triamcinolone; and oral nicotinamide, acitretin, methotrexate, and cyclophosphamide. Similarly, GEKA has been linked to HPV 39 infection, and sporadic keratoacanthomas have shown positivity with multiple HPV subtypes, but this testing is not currently available at our institution. Further testing is indicated to determine the significance of these genetic findings and to explore the role of HPV in GEKA."

Clinical • Late-breaking abstract • Dermatology • Infectious Disease • Oncology • Squamous Cell Carcinoma • TGFBR1 • XPC

Cell-specific genetic effects of topical glucocorticoids in human skin (SID 2025) - "Here, we performed single-cell RNA and ATAC sequencing on paired skin samples from human subjects (n=4), comparing sites treated with clobetasol propionate to vehicle controls...These intercellular signaling changes highlight the complex cross-talk among resident skin cell types impacted by GCs, shaping their broad biological effects. In summary, our findings define the diverse genetic and intercellular effects of topical GCs in vivo, providing new insights into their mechanisms of action and informing strategies to optimize their use."

Dermatitis • Dermatology • Immunology • Inflammation • Rosacea • IFNG • IL2 • SEMA3A • STAT5 • STAT5AWqe

Systematic review of lichen planus treatments for pediatric patients (SID 2025) - "5 studies reported symptom resolution with 4-8 weeks of clobetasol 0.05%. One study reported symptom improvement in 17 patients with triamcinolone acetonide 0.1% ointment for 8 weeks...Oral prednisolone was reported in 9 studies with dosages ranging from 5mg to 30mg and durations ranging from 2 weeks to 1 year; 66.6% of these studies reported complete symptom resolution...Immunomodulators were reported in 5 studies, including upadacitinib, cyclosporine, sulfasalazine, and azathioprine. Recently published reviews highlight treatment approaches for LP subtypes like oral, nail, and lichen planus pigmentosus, but current literature lacks a comprehensive review of treatment options for classic LP in children. While topical corticosteroids remain the cornerstone of pediatric LP treatment, emerging modalities like immunomodulators and phototherapy hold promise but require further validation."

Clinical • Review • Dermatology • Dermatopathology • Lichen Planus • Pediatrics

Successful bimekizumab treatment for palmoplantar psoriasis in skin of color (SID 2025) - "He failed multiple treatments, including topical therapies (triamcinolone .1%, clobetasol .05%, tapinarof, roflumilast), biologics (secukinumab, adalimumab), and four prednisone courses, which provided temporary relief but led to rebound flares once tapered. This patient's response to bimekizumab underscores the value of targeting immune pathways in refractory cases and the risks of long-term corticosteroid use. Bimekizumab offers a promising option for refractory PPP, providing symptom relief and a strong safety profile, especially for patients with skin of color who may have unique immune risks."

Cardiovascular • Coronary Artery Disease • Dermatology • Diabetes • Dyslipidemia • Hypertension • Immunology • Metabolic Disorders • Pain • Pruritus • Psoriasis • Type 2 Diabetes Mellitus • IL17A

Efficacy of 0.5% Timolol Maleate versus 0.05% Clobetasol Propionate in Treating Superficial Infantile Hemangioma: A Pilot Randomized Controlled Trial. (PubMed, J Indian Assoc Pediatr Surg) - "To compare the efficacy of two topical agents in superficial infantile hemangioma (SIH)...In arm I, two patients were transitioned from TTM to oral propranolol due to rapid progression deep into the dermis...0.5%-TTM solution can be a first-line therapy for SIH due to its rapid onset of action and overall comparable efficacy in reducing SIH size. While clobetasol remains effective, its slower response may limit its utility."

Journal • Oncology

Treatment Patterns in the Management of Alopecia Areata in a Colombian HMO During 2015-2023: A Real-World Data Study (ISPOR 2025) - "From 13,807 pharmacological claims, topical betamethasone (38.4%), hydrocortisone (36.4%) and injectable betamethasone (5.1%) were the most common. The observed AA patients were mostly female middle-aged adults who have been mainly diagnosed and followed by a GP, and the most frequent treatment was topical betamethasone, and the most persistent treatment was clobetasol."

Clinical • Real-world • Real-world evidence • Alopecia • Dermatology • Immunology • Novel Coronavirus Disease

Skin lightening cream causing hypoadrenalism (ESPE-ESE 2025) - "She has a past medical history of depression and anxiety and was taking mirtazapine medication...She denied taking oral or inhaled steroids but on further questioning it was found she has been taking a skin lightening cream call ‘Fashion fair cream’ which contains clobetasol propionate...She was reviewed in the endocrine clinic where she was advised to stop her topical cream and started on hydrocortisone 10mg/5mg/5mg with aim to wean down slowly Conclusion Many skin lightening creams contain steroids which patients may not be aware of...It is important to take a full history to check if patients are taking topical cream, eye drops, etc that may contain steroids. It is also important to have an MDT approach with the dermatologist and endocrinologist to help wean patient off the steroids and treat appropriately."

Atopic Dermatitis • CNS Disorders • Depression • Dermatology • Endocrine Disorders • Fatigue • Genetic Disorders • Immunology • Mood Disorders • Nephrology • Obesity • Psoriasis • Psychiatry • Renal Disease

The Prevalence and The Diagnosis Of Glucocorticoids-Induced Adrenal Insufficiency: A Systematic Review (ESPE-ESE 2025) - "Abstract Introduction: Glucocorticoid-induced adrenal insufficiency (GC-induced AI) remains a common although under-recognised cause of morbidity in patients on chronic steroid therapy for a wide array of therapeutic indications. Twenty-one studies met the inclusion criteria, reporting AI prevalence ranging from 7.8% for inhaled GCs to 63% for oral high dose GCs used on short-term. Oral prednisolone doses ≥15 mg/day for >3 months carried the highest risk of developing iatrogenic AI. Inhaled fluticasone >800 mcg/day and super-potent topical clobetasol >50 g/week posed significant clinical risks."

Review • Endocrine Disorders • Nephrology • Renal Disease